Sandoz (SDZ.SW) reported first quarter net sales of $2.76 billion compared to $2.48 billion, prior year. Sandoz said its performance was in line with company expectations. The company confirmed its guidance for 2026.
Overall net sales were up by 3% at CC, and by 5% when excluding effect of adverse dynamics in anti-infective B2B business. Biosimilar net sales were up by 18% at CC, with generics net sales declining by 3% at CC. Underlying generics net sales declined by 1% at CC when excluding anti-infective B2B impact.
The company intends to publish half-year results on 5 August 2026.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.